Observable score for bleeding after colorectal endoscopic mucosal resection.

IF 3.4 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY
Therapeutic Advances in Gastroenterology Pub Date : 2025-07-20 eCollection Date: 2025-01-01 DOI:10.1177/17562848251356112
Hayato Nakazawa, Kenichiro Okimoto, Tomoaki Matsumura, Masayuki Yokoyama, Tsubasa Ishikawa, Yoshihiro Fukuda, Yoshio Kitsukawa, Akane Kurosugi, Michiko Sonoda, Tatsuya Kaneko, Yuki Ohta, Takashi Taida, Keisuke Matsusaka, Jun-Ichiro Ikeda, Jun Kato
{"title":"Observable score for bleeding after colorectal endoscopic mucosal resection.","authors":"Hayato Nakazawa, Kenichiro Okimoto, Tomoaki Matsumura, Masayuki Yokoyama, Tsubasa Ishikawa, Yoshihiro Fukuda, Yoshio Kitsukawa, Akane Kurosugi, Michiko Sonoda, Tatsuya Kaneko, Yuki Ohta, Takashi Taida, Keisuke Matsusaka, Jun-Ichiro Ikeda, Jun Kato","doi":"10.1177/17562848251356112","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>There is insufficient evidence regarding the management of hematochezia after colorectal endoscopic mucosal resection (EMR) without endoscopic hemostasis.</p><p><strong>Objectives: </strong>The aim of this study was to develop an observable score for hematochezia after colorectal EMR.</p><p><strong>Design: </strong>Retrospective study.</p><p><strong>Methods: </strong>This retrospective study included three hospitals in Japan. During the study period, colorectal EMR was performed in 3989 patients (11,414 lesions). Post-EMR hematochezia (delayed bleeding (DB)) was observed in 169 patients (512 lesions). Of these, 47 patients (150 lesions) were classified into the Hemostasis Group, comprising those who underwent endoscopic hemostasis. The remaining 122 (362 lesions) were classified into the non-hemostasis group, comprising those who underwent endoscopy without hemostasis, received preventive hemostasis, and did not undergo emergency endoscopy. Weighted points were assigned to predict observable cases following colorectal EMR through multivariate logistic regression analysis, enabling the development of a predictive model.</p><p><strong>Results: </strong>The prediction model comprised three variables (male gender, American Society of Anesthesiologists Physical Status 3, direct oral anticoagulant). According to the definition, the total score was categorized as lowly observable (2 or 3 points) and highly observable (0 or 1 points) for DB after colorectal EMR. As a result, the rates of observable cases for each risk category were 45.7% and 81.8%, respectively. The model showed good discrimination ability from the c-statistic (95% CI) of 0.71 (0.63-0.79).</p><p><strong>Conclusion: </strong>Although further prospective studies are necessary to validate the utility of the score, it may be useful in clinical practice.</p>","PeriodicalId":48770,"journal":{"name":"Therapeutic Advances in Gastroenterology","volume":"18 ","pages":"17562848251356112"},"PeriodicalIF":3.4000,"publicationDate":"2025-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12280549/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17562848251356112","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: There is insufficient evidence regarding the management of hematochezia after colorectal endoscopic mucosal resection (EMR) without endoscopic hemostasis.

Objectives: The aim of this study was to develop an observable score for hematochezia after colorectal EMR.

Design: Retrospective study.

Methods: This retrospective study included three hospitals in Japan. During the study period, colorectal EMR was performed in 3989 patients (11,414 lesions). Post-EMR hematochezia (delayed bleeding (DB)) was observed in 169 patients (512 lesions). Of these, 47 patients (150 lesions) were classified into the Hemostasis Group, comprising those who underwent endoscopic hemostasis. The remaining 122 (362 lesions) were classified into the non-hemostasis group, comprising those who underwent endoscopy without hemostasis, received preventive hemostasis, and did not undergo emergency endoscopy. Weighted points were assigned to predict observable cases following colorectal EMR through multivariate logistic regression analysis, enabling the development of a predictive model.

Results: The prediction model comprised three variables (male gender, American Society of Anesthesiologists Physical Status 3, direct oral anticoagulant). According to the definition, the total score was categorized as lowly observable (2 or 3 points) and highly observable (0 or 1 points) for DB after colorectal EMR. As a result, the rates of observable cases for each risk category were 45.7% and 81.8%, respectively. The model showed good discrimination ability from the c-statistic (95% CI) of 0.71 (0.63-0.79).

Conclusion: Although further prospective studies are necessary to validate the utility of the score, it may be useful in clinical practice.

结肠内镜下粘膜切除术后出血的观察评分。
背景:没有内镜下止血的结肠内镜粘膜切除术(EMR)后便血的处理证据不足。目的:本研究的目的是建立结肠直肠EMR后便血的可观察评分。设计:回顾性研究。方法:对日本三家医院进行回顾性研究。在研究期间,对3989例患者(11414个病变)进行了结肠直肠EMR。emr后出现便血(延迟出血(DB)) 169例(512个病灶)。其中,47例患者(150个病变)被分为止血组,包括那些接受内窥镜止血的患者。其余122例(362例)归为非止血组,包括未止血的内镜检查、预防性止血和未急诊内镜检查。通过多变量logistic回归分析,分配加权点来预测结直肠EMR后的可观察病例,从而建立预测模型。结果:预测模型包含3个变量(男性性别、美国麻醉医师协会身体状况3、直接口服抗凝剂)。根据定义,将结直肠EMR术后DB总分分为低可观察性(2分或3分)和高可观察性(0分或1分)。结果,各风险类别的可观察病例率分别为45.7%和81.8%。c统计量(95% CI)为0.71(0.63-0.79),模型具有良好的判别能力。结论:虽然需要进一步的前瞻性研究来验证该评分的实用性,但它可能在临床实践中有用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Therapeutic Advances in Gastroenterology
Therapeutic Advances in Gastroenterology GASTROENTEROLOGY & HEPATOLOGY-
CiteScore
6.70
自引率
2.40%
发文量
103
审稿时长
15 weeks
期刊介绍: Therapeutic Advances in Gastroenterology is an open access journal which delivers the highest quality peer-reviewed original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of gastrointestinal and hepatic disorders. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in gastroenterology and related disciplines, providing an online forum for rapid dissemination of recent research and perspectives in this area. The editors welcome original research articles across all areas of gastroenterology and hepatology. The journal publishes original research articles and review articles primarily. Original research manuscripts may include laboratory, animal or human/clinical studies – all phases. Letters to the Editor and Case Reports will also be considered.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信